We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
+0.46%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$2.76B
AUM Growth
+$477M
(+21%)
Cap. Flow
+$295M
Cap. Flow
% of AUM
10.72%
Top 10 Holdings %
Top 10 Hldgs %
40.13%
Holding
124
New
45
Increased
34
Reduced
15
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Williams-Sonoma
WSM
|
+$39.5M |
| 2 |
Alkermes
ALKS
|
+$38.6M |
| 3 |
Coca-Cola
KO
|
+$31.2M |
| 4 |
SPPI
Spectrum Pharmaceuticals Inc
SPPI
|
+$28.8M |
| 5 |
Altimmune
ALT
|
+$28.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dropbox
DBX
|
+$35.4M |
| 2 |
Dollar General
DG
|
+$35.3M |
| 3 |
Biogen
BIIB
|
+$32.4M |
| 4 |
AptarGroup
ATR
|
+$32.3M |
| 5 |
Best Buy
BBY
|
+$29M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.21% |
| 2 | Consumer Discretionary | 12.09% |
| 3 | Consumer Staples | 9.81% |
| 4 | Industrials | 2.38% |
| 5 | Technology | 1.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Deckers Outdoor
DECK
$13.4B
| $17.5M | 0.64% |
+478,530
| New | +$16.5M |
|
52
CRISPR Therapeutics
CRSP
$5.06B
| $17.1M | 0.62% |
204,000
+16,000
| +9% | +$1.42M |
|
53
Viatris
VTRS
$19.6B
| $16.7M | 0.61% |
+1,128,000
| New | +$18M |
|
54
Five Below
FIVE
$12.6B
| $15.8M | 0.57% |
124,200
-253,805
| -67% | -$28.9M |
|
55
Jack in the Box
JACK
$334M
| $13.9M | 0.5% |
175,438
+39,735
| +29% | +$3.2M |
|
56
Avantor
AVTR
$8.87B
| $13.8M | 0.5% |
+612,000
| New | +$12.7M |
|
|
HRC
57
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $13.7M | 0.5% |
+164,000
| New | +$16.1M |
|
58
Assembly Biosciences
ASMB
$521M
| $12.6M | 0.46% |
64,000
+14,333
| +29% | +$3.61M |
|
|
ADMS
59
DELISTED
Adamas Pharmaceuticals
ADMS
| $11.3M | 0.41% |
2,742,000
| – | – |
|
|
GNMK
60
DELISTED
GenMark Diagnostics, Inc
GNMK
| $11.2M | 0.41% |
+792,000
| New | +$12.1M |
|
|
AVYA
61
DELISTED
Avaya Holdings Corp. Common Stock
AVYA
| $11.2M | 0.41% |
736,000
-1,100,000
| -60% | -$15.5M |
|
|
CLVS
62
DELISTED
Clovis Oncology, Inc.
CLVS
| $10.8M | 0.39% |
1,848,000
+248,000
| +16% | +$1.48M |
|
|
OBSV
63
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $10.8M | 0.39% |
+4,338,927
| New | +$12.4M |
|
64
Bio-Rad Laboratories Class A
BIO
$9.12B
| $10.3M | 0.37% |
+20,000
| New | +$10.1M |
|
|
GAP
65
The Gap Inc
GAP
$7.39B
| $8.52M | 0.31% |
+500,000
| New | +$7.45M |
|
66
Aurinia Pharmaceuticals
AUPH
$2.07B
| $7.37M | 0.27% |
+500,000
| New | +$7.24M |
|
|
ETTX
67
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
| $7.16M | 0.26% |
+3,510,981
| New | +$10M |
|
|
AXNX
68
DELISTED
Axonics, Inc. Common Stock
AXNX
| $7.15M | 0.26% |
+140,000
| New | +$5.84M |
|
69
Kiora Pharmaceuticals
KPRX
$11.3M
| $7.12M | 0.26% |
5,043
| – | – |
|
70
Thermo Fisher Scientific
TMO
$212B
| $7.06M | 0.26% |
16,000
-8,000
| -33% | -$3.31M |
|
|
FREE
71
DELISTED
Whole Earth Brands, Inc. Class A Common Stock
FREE
| $6.87M | 0.25% |
+824,000
| New | +$6.48M |
|
72
Microsoft
MSFT
$3.69T
| $6.73M | 0.24% |
+32,000
| New | +$6.72M |
|
|
AVNS
73
DELISTED
Avanos Medical
AVNS
| $6.54M | 0.24% |
+197,000
| New | +$6.3M |
|
|
CFMS
74
DELISTED
Conformis, Inc. Common Stock
CFMS
| $6.26M | 0.23% |
+299,095
| New | +$5.71M |
|
75
SI-BONE Inc
SIBN
$796M
| $6.07M | 0.22% |
+256,000
| New | +$5.09M |
|
Similar funds
CRC
RMDI
F
EW
O
DSC
ACM
PI
Armistice Capital's Q3 2020 Portfolio in Review
As of Q3 2020, Armistice Capital held 124 positions worth $2.76B, up 21% from $2.28B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Armistice Capital deployed $295M of net new capital in Q3 2020, opening 45 new positions and adding to 34 existing holdings. Its largest new stake was Williams-Sonoma: 890,000 shares worth $40.2M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 45% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was Biogen, an estimated $32.4M trimmed.
- Armistice Capital's largest Q3 2020 buy was Williams-Sonoma: 890,000 shares worth $40.2M.
- Armistice Capital added most to AutoZone in Q3 2020, an estimated $27.5M increase.
- Armistice Capital's biggest Q3 2020 reduction was Biogen, cutting an estimated $32.4M.
- Armistice Capital fully exited Dropbox in Q3 2020, selling an estimated $35.4M.
- Armistice Capital's ten largest holdings make up 40% of its $2.76B portfolio in Q3 2020.
- Armistice Capital opened 45 new positions and closed 23 in Q3 2020.
- Armistice Capital's portfolio value rose 21% quarter-over-quarter to $2.76B.
Based on Armistice Capital's 13F filing for Q3 2020, filed 16 Nov 2020.